24/7 Wall Street
15 Jul 2026, 11:45 UTC · 17w ago
Verdict
Headline takes no side. We score ABBV +0.90 across five claims — strongly bullish.
+0.90strongly bullish
More positive than 95% of ticker scores this week
Scored by the NIS engine · methodology.
Search tags
What the story claims
5 claims · scored −1 bearish … +1 bullish
AbbVie raised its full-year adjusted EPS guidance to a range of $14.08 to $14.28 following strong Q1 2026 results.
More positive than 93% of claims this week
Baxter International reported a FY2025 net loss of $900 million and effectively eliminated its dividend payout.
Continue reading
5 related stories
More negative than 93% of claims this week
AbbVie's Skyrizi and Rinvoq drugs grew 31% and 23% respectively in Q1 2026, offsetting biosimilar losses for Humira.
More positive than 76% of claims this week
Baxter's 2026 adjusted EPS guidance of $1.85 to $2.05 represents a step-down from the previous $2.27.
More negative than 75% of claims this week
Both AbbVie and Baxter recently exhibited a 'golden cross' technical signal, though AbbVie's is widening while Baxter's is narrow and on a declining 200-day average.
More positive than 42% of claims this week
Which stocks this story touches
More positive than 95% of ticker scores this week
The company reported strong growth in Skyrizi and Rinvoq, raised full-year guidance, and maintains a growing dividend.
More negative than 94% of ticker scores this week
The company eliminated its dividend, posted significant net losses for FY2025, and is described as a speculative turnaround play.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
The Motley Fool
1h ago
+21.1%
Price agrees with the score
$296.37 vs $244.78 close before publication (Jul 14) · not market-adjusted
ABBV chart →
